Speciality: Oncology
Description:
A warm welcome to all the medical professionals in this interesting learning session on first line management of ALK positive lung cancer.
In this webinar, a panel discussion would take place involving Dr. Jessicca Lin as the primary speaker and Dr. T. Raja, Dr. Amit Rauthan, Dr. B. K. Smruti and many other panelists who will share the important facts associated with first line management of ALK positive lung cancer.
Starting with the case scenario of non-small cell lung cancer, Dr Jessica has explained all details associated with the incidence, progression and treatment of ALK positive lung cancer. Further, the panel discussion will give more knowledge.
ALK-positive lung cancer represents about 4% of lung cancer which generally appears in adenocarcinoma non-small cell lung cancer. Patients with ALK-positive are mostly younger than the average lung cancer patient and also do not have a smoking history compared to other lung cancers.
Therefore, you are going to have an overall knowledge regarding management of ALK positive lung cancer. Listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Ivonescimab Tops Pembrolizumab in PD-L1-Positive, Advanced NSCLC
2.
Virtual Reality Travel Reduces Cancer Pain.
3.
NEJM: Pirtobrutinib is effective in CLL patients who have received prior BTK inhibitor therapy.
4.
Even a few mutated cells can significantly impact how blood cancers develop, study finds
5.
Omitting Biopsy After Negative MRI Halves Diagnoses of Insignificant Prostate Cancer
1.
Circulating Tumor Cells & Platelet Interactions: Crosstalk for Therapeutic Advances
2.
Optimizing Oncology Practice Revenue: Billing Software, Payer Trends, and Financial Navigation Tools
3.
AI-Powered Case Studies in Oncology: Elevating Clinical Influence Through Real-World Data
4.
Everything You Need to Know About Leiomyomas: A Comprehensive Guide
5.
Seeing the Unseen: Examining Chancroid Through Images
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VI
2.
Newer Immunotherapies for Myeloma- A Comprehensive Overview- Part II
3.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC - Part VII
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation